Prednisolone 40 mg/day* or greater for more than 1 week, or 10mg/day or greater for 2 weeks or longer.
Cyclophosphamide, Rituximab, Alemtuzumab, Cladribine or Ocrelizumab in the last 6 months.
People with autoimmune disease and with clinical immunosuppression manifest by recurrent infections and/or significant laboratory evidence of immunosuppression (severe neutropenia (ANC less than 0.5 x 109/L), lymphopenia & hypogammaglobulinaemia).”
* From HSE COVID-19: Interim Clinical Guidance: Immunosuppressant Therapy v5 updated 29th October 2020)
(a) Patients on Methotrexate
(b) Patients on Corticosteroids
(c) Patients on Rituximab
Figure 1 – mechanisms of SARS-CoV-2 vaccines
Table 1 – Vaccines in Phase 3 trials 1/12/20
National Health Library & Knowledge Service. Health Service Executive. Dr. Steevens' Hospital, Dublin 8. Tel: 01-6352555/8. Email: email@example.com